^
Association details:
Biomarker:MLL2 mutation
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

EP16.01-007 - Molecular Characterization by Next-Generation Sequencing (NGS) of Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy

Published date:
07/12/2022
Excerpt:
We conducted a retrospective study, which included patients diagnosed with NSCLC in our hospital from Jul-15 to Jan-21 and treated with immunotherapy...Note that in the group of MLL2 mutated, PFS was 8.6 months (CI: 1.5-15.8) vs 13.3 months in the MLL2 wild-type group (CI, not reached). This data could indicate a better response to immunotherapy in this subgroup.